Cocrystal Pharma Inc
COCP
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
There are 3 good reasons to buy this US dividend stock today
It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.
stocks
Strategic reset for ASX listed share
The global search for a new CEO is over, ending investor concern about leadership uncertainty.
stocks
ASX listed bank overvalued after shares surge
Investors were pleased with results but our fair value estimate is unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.80 | 5.80 | -0.06% |
| CAC 40 | 8,334.33 | 22.59 | 0.27% |
| DAX 40 | 24,923.42 | 8.54 | 0.03% |
| Dow JONES (US) | 49,500.93 | 48.95 | 0.10% |
| FTSE 100 | 10,465.55 | 19.20 | 0.18% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,806.41 | 135.56 | -0.24% |
| NZX 50 Index | 13,117.91 | 80.27 | -0.61% |
| S&P 500 | 6,836.17 | 3.41 | 0.05% |
| S&P/ASX 200 | 8,937.10 | 8.30 | -0.09% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |